header logo image


Page 99«..1020..9899100101..110120..»

Aiming for longevity – Harvard Health

December 22nd, 2023 2:38 am

Helen Mongelia's 102 years reflect the mysterious alchemy of genetic, environmental, and lifestyle factors that coalesce to aid longevity. Fresh food, consistent movement, emotional resilience, and a family full of long-living relatives mark the centenarian's colorful life span, which began in 1919 while Woodrow Wilson occupied the White House.

Longevity like Mrs. Mongelia's remains extraordinary, with an estimated one in 6,000 people in the United States reaching 100 nowadays, according to the U.S. Administration on Aging. More than 100,000 were 100 or older in 2019, triple the number in 1980 who'd passed their 100th birthday.

Scientists, including those at Harvard, are eagerly studying people in their 90s and beyond to tease out what contributes to exceptionally long living. People enduring to extreme old age often have lifestyles that fuel vigor and hamper age-related chronic diseases such as heart disease, cancer, and diabetes. They typically are nonsmokers, are not obese, and cope effectively with stress, according to the National Institutes of Health (NIH). Most are women.

"I didn't expect to live this long, that's for sure," says Mrs. Mongelia, who lived independently until 101 when she also gave up driving and happily holds a mailroom job at her assisted living residence in Connecticut. "But I've tried not to let anything bother me too much. I have two great daughters, two sons-in-law, and two grandchildren what else can you ask for? There's my happiness right there."

Mrs. Mongelia never restricted her diet, eating meat but skipping most alcoholic drinks. But her early fare as the middle child of 11 was abundant in fruits and vegetables, many grown in her family's garden in Carbondale, Pa., and canned to enjoy all year long. The large clan also walked "everywhere," trekking miles round-trip to church, school, and the grocery store.

Mrs. Mongelia's healthy habits hit a sweet spot that science increasingly spotlights as optimal for longevity. A new Harvard-led study spanning 11 years and involving 2,400 people (average age 60; 55% women) suggests that a Mediterranean diet rich in fruits, vegetables, and healthy fats may dampen inflammation and prevent age-related frailty, a major predictor of decline affecting between 10% and 15% of older adults.

"Frailty is hard to define, but it's really easy to spot. In general, it's a state of increased vulnerability," says Courtney Millar, a postdoctoral research fellow at the Marcus Institute for Aging Research at Harvard-affiliated Beth Israel Deaconess Medical Center.

"It's important to focus on frailty prevention and treatment, because it's associated with so many of the factors that determine someone's longevity," says Millar, a co-author of the study, published online May 12, 2022, by The American Journal of Clinical Nutrition.

Another new study suggests that young adults who begin optimizing their diets at age 20 by veering from typical Western fare to more whole grains, legumes, and nuts could increase their life expectancy by more than a decade. Published online Feb. 8, 2022, by PLOS Medicine, the study posited that people who start such dietary shifts even at age 60 can still reap substantial benefits, increasing life expectancy by eight years for women; 80-year-olds could gain another three-plus years.

"I'm certainly a believer that food is medicine," Millar says, "and there's some great evidence that dietary factors can improve longevity."

Mrs. Mongelia's family is peppered with relatives who've had far longer-than-average life spans. Although her coal miner father died of black lung disease at 78, Mrs. Mongelia's mother lived to 93, and many siblings also thrived into their 10th decade. Two brothers still survive.

Research reinforces this link: siblings and children of long-living people are more likely to live beyond peers and remain healthier while doing so, according to the NIH. A study published online May 28, 2022, by The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences suggested that children of those who reach 100 carry a specific "genetic footprint" explaining why they're less frail than peers whose parents were not centenarians.

Might our genes be the linchpin to longevity? "My take is that it's certainly a combination of lifestyle and genetics," Millar says. "Certain dietary factors and even exercise regimens can modify how our genes are expressed and contribute to what's going on in our bodies. It's a really important intersection of our health."

Some scientists use the term "biohacks" to refer to tweaks in daily habits and choices that aim to tamp down inflammation and blunt aging's effects. Many of these tactics aren't new, but Harvard experts say that employing them consistently might contribute to longevity.

Move more. Vigorous movement has repeatedly been linked with lower risks of heart disease, diabetes, obesity, and other chronic health problems.

Review your health history. Talk to your primary care doctor about your health conditions and any new symptoms so you can manage them appropriately.

Try intermittent fasting. Compressing meals into a six- or eight-hour window each day boosts the body's natural process of eliminating damaged cells and proteins, lowering inflammation levels.

Eat a plant-forward diet. Antioxidants from fruits and vegetables and fiber from whole grains all help to lower inflammation levels. Beans, chickpeas, and other legumes were hailed as a key dietary predictor of longevity in a study that found a daily dietary increase of just 20 grams (less than an ounce) of legumes lowers our risk of dying in any given year by 8%.

Boost your outlook. List your life goals and imagine a future where they've been reached, or think about three good things that happened to you every day. Write them down.

Despite a hardscrabble path that included dropping out of school after 11th grade to take care of a baby sibling and also working as a button operator in a dress factory where she earned three cents per dozen buttons mounted Mrs. Mongelia maintains an upbeat attitude that matches her hardy body. She relies on a walker and hearing aids, but remains mentally sharp. "Just keep going and going and going, and don't give up," she counsels.

A recent Harvard-led analysis of nearly 160,000 American women linked positive outlook to extended life span. Published online June 8, 2022, by the Journal of the American Geriatrics Society, the study analyzed data and survey responses from women who were 50 to 79 years old when they enrolled in the study in the 1990s. The researchers then tracked participants' survival for up to 26 years. The results suggested that higher levels of optimism correlated with higher odds of living beyond 90.

About a quarter of the relationship between optimism and living longer may reflect health-related factors such as eating healthy foods, controlling weight, exercising, and limiting alcohol, says study co-author Dr. Hayami Koga, a researcher and doctoral candidate in population health sciences at the Harvard T.H. Chan School of Public Health.

The findings hint at the value of focusing on positive psychological factors as possible new ways of promoting longevity and healthy aging, Dr. Koga says. "There's some evidence that optimistic people are more likely to have goals and the confidence to reach them," she adds. "I think it drives people to be more confident and take actions that lead to better health."

Photo by Timothy H. Cole

Originally posted here:
Aiming for longevity - Harvard Health

Read More...

How Long Can We Live? – The New York Times

December 22nd, 2023 2:38 am

As medical and social advances mitigate diseases of old age and prolong life, the number of exceptionally long-lived people is increasing sharply. The United Nations estimates that there were about 95,000 centenarians in 1990 and more than 450,000 in 2015. By 2100, there will be 25 million. Although the proportion of people who live beyond their 110th birthday is far smaller, this once-fabled milestone is also increasingly common in many wealthy nations. The first validated cases of such supercentenarians emerged in the 1960s. Since then, their global numbers have multiplied by a factor of at least 10, though no one knows precisely how many there are. In Japan alone, the population of supercentenarians grew to 146 from 22 between 2005 and 2015, a nearly sevenfold increase.

Given these statistics, you might expect that the record for longest life span would be increasing, too. Yet nearly a quarter-century after Calments death, no one is known to have matched, let alone surpassed, her 122 years. The closest was an American named Sarah Knauss, who died at age 119, two years after Calment. The oldest living person is Kane Tanaka, 118, who resides in Fukuoka, Japan. Very few people make it past 115. (A few researchers have even questioned whether Calment really lived as long as she claimed, though most accept her record as legitimate based on the weight of biographical evidence.)

As the global population approaches eight billion, and science discovers increasingly promising ways to slow or reverse aging in the lab, the question of human longevitys potential limits is more urgent than ever. When their work is examined closely, its clear that longevity scientists hold a wide range of nuanced perspectives on the future of humanity. Historically, however and somewhat flippantly, according to many researchers their outlooks have been divided into two broad camps, which some journalists and researchers call the pessimists and the optimists. Those in the first group view life span as a candle wick that can burn for only so long. They generally think that we are rapidly approaching, or have already reached, a ceiling on life span, and that we will not witness anyone older than Calment anytime soon.

In contrast, the optimists see life span as a supremely, maybe even infinitely elastic band. They anticipate considerable gains in life expectancy around the world, increasing numbers of extraordinarily long-lived people and eventually, supercentenarians who outlive Calment, pushing the record to 125, 150, 200 and beyond. Though unresolved, the long-running debate has already inspired a much deeper understanding of what defines and constrains life span and of the interventions that may one day significantly extend it.

The theoretical limits on the length of a human life have vexed scientists and philosophers for thousands of years, but for most of history their discussions were largely based on musings and personal observations. In 1825, however, the British actuary Benjamin Gompertz published a new mathematical model of mortality, which demonstrated that the risk of death increased exponentially with age. Were that risk to continue accelerating throughout life, people would eventually reach a point at which they had essentially no chance of surviving to the next year. In other words, they would hit an effective limit on life span.

Read the rest here:
How Long Can We Live? - The New York Times

Read More...

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

December 22nd, 2023 2:37 am

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024. Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring. Riggsbee will continue as a strategic advisor through March 31, 2024, to ensure a smooth transition.

Read this article:
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

Read More...

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

December 22nd, 2023 2:37 am

Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease

Read the rest here:
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

Read More...

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

December 22nd, 2023 2:37 am

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) before and after surgery with curative intent.

Continued here:
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Read More...

Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive…

December 22nd, 2023 2:37 am

-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care

Read more from the original source:
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive...

Read More...

Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument…

December 22nd, 2023 2:37 am

New System Saves Time and Resources, Improves Efficiency and Accuracy New System Saves Time and Resources, Improves Efficiency and Accuracy

More here:
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument...

Read More...

Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced…

December 22nd, 2023 2:37 am

MINNEAPOLIS, Dec. 21, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,556,000 shares of its common stock, in the aggregate, to exercise outstanding warrants at the existing exercise price of $0.78 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.0 million, before deducting financial advisory fees. The exercisability of the new warrants and any resulting issuance of the shares underlying the new warrants are subject to stockholder approval in accordance with Nasdaq rules.

Follow this link:
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced...

Read More...

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

December 22nd, 2023 2:37 am

Continue reading here:
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

Read More...

CARBIOS publishes its second sustainability report and confirms its ambitions to accelerate the circular economy for plastic

December 22nd, 2023 2:37 am

PRESS RELEASE

Link:
CARBIOS publishes its second sustainability report and confirms its ambitions to accelerate the circular economy for plastic

Read More...

Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome

December 22nd, 2023 2:37 am

Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome

Visit link:
Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome

Read More...

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

December 22nd, 2023 2:37 am

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)

Follow this link:
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Read More...

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

December 22nd, 2023 2:37 am

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 –

Read more here:
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Read More...

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

December 22nd, 2023 2:37 am

Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ? 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a clinical fibrosis target Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ? 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a clinical fibrosis target

Read the rest here:
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Read More...

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

December 22nd, 2023 2:37 am

REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 42nd Annual Health Care Conference in San Francisco, CA.

Read more:
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

Read More...

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

December 22nd, 2023 2:37 am

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024.

See the original post here:
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

Read More...

Evaxion Biotech Announces Closing of Private Placement

December 22nd, 2023 2:37 am

COPENHAGEN, Denmark, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of its previously announced private placement (the “Private Placement”) with a gross proceed of $5.3 million. The Private Placement included participation from existing and new shareholders, with the largest new shareholder being MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, accounting for some 25% of the total aggregate offering amount. Further, the Private Placement included significant participation by all members of the Company’s management and the Company’s board of directors.

See more here:
Evaxion Biotech Announces Closing of Private Placement

Read More...

Lowell Farms Inc. Announces Resignation of Board Member Brian Shure

December 22nd, 2023 2:37 am

SALINAS, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born vertically integrated cannabis company with advanced production capabilities including extraction, manufacturing, and distribution, announces that effective December 19, 2023, Brian Shure has announced his resignation from the Lowell Farms Inc. Board of Directors for personal reasons.

Read the original:
Lowell Farms Inc. Announces Resignation of Board Member Brian Shure

Read More...

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of…

December 22nd, 2023 2:37 am

LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 - 14, 2024 in Salt Lake City, Utah. The poster will be presented by MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology at The University of Texas Medical Branch.

Here is the original post:
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of...

Read More...

Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth

December 22nd, 2023 2:37 am

TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%. Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group. This significant decision not only allows Polaris Group to expand the product pipeline beyond its novel cancer metabolism therapy but also marks its entry into the highly promising realm of peptide drugs, such as the widely recognized Semaglutide-related products. These two highly prospective product lines will serve as the dual engines propelling Polaris Group's future growth.

Read more:
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth

Read More...

Page 99«..1020..9899100101..110120..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick